Sustained expression of human factor VIII in mice using a parvovirus-based vector.
Chao H, Mao L, Bruce AT, Walsh CE.
Blood. 2000 Mar 1;95(5):1594-9.
PMID: 10688813
Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to haemophiliaA gene therapy.
Gnatenko DV, Saenko EL, Jesty J, Cao LX, Hearing P, Bahou WF.
Br J Haematol. 1999 Jan;104(1):27-36.
PMID: 10027708
Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa.
Pipe SW, Saenko EL, Eickhorst AN, Kemball-Cook G, Kaufman RJ.
Blood. 2001 Feb 1;97(3):685-91.
PMID: 11157485
Stability and sterility of a recombinant factor VIII concentrate prepared for continuous infusion administration.
Belgaumi AF, Patrick CC, Deitcher SR.
Am J Hematol. 1999 Sep;62(1):13-8.
PMID: 10467271
Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo.
Pipe SW, Eickhorst AN, McKinley SH, Saenko EL, Kaufman RJ.
Blood. 1999 Jan 1;93(1):176-83.
PMID: 9864159
Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M.
Lee C, Barrowcliffe T, Bray G, Gomperts E, Hubbard A, Kemball-Cook G, Lilley P, Owens D, Von Tilberg L, Pasi J.
Thromb Haemost. 1996 Dec;76(6):950-6.
PMID: 8972016